by Clay Adams | Dec 31, 2025 | News/Announcement, Press Release
Idaho Falls, ID – December 30th, 2025 – International Isotopes Inc. (“INIS” or the “Company”) (OTCQB:INIS) today announced that it has filed a Certificate of Amendment in the State of Texas to change our legal name to Radnostix, Inc. Effective immediately, we will...
by Clay Adams | Nov 14, 2025 | Press Release
IDAHO FALLS, IDAHO, November 14, 2025. International Isotopes Inc. (OTCQB: INIS) (the “Company” or “INIS”) is pleased to announce its financial results for the third quarter and nine months ended September 30, 2025. Revenue from the sale of product for the third...
by Clay Adams | Oct 23, 2025 | News/Announcement, Press Release
IDAHO FALLS, Idaho & LANE COVE, Australia – October 23, 2025. International Isotopes, Inc. (“INIS”), a leading U.S. provider of medical isotopes and nuclear medicine solutions, today announced an exclusive partnership agreement with Australia-based...
by Clay Adams | Oct 22, 2025 | Press Release
Idaho Falls, ID – October 22th, 2025 – International Isotopes Inc. (OTCQB: INIS) (“INIS” or the “Company”), a leading provider of radiopharmaceuticals, radioisotope products, and nuclear medicine solutions, has appointment of Dr. Duke W. Fu to its Board of Directors,...
by Clay Adams | Aug 25, 2025 | Press Release
Sale of product for the first six months of 2025 increased 13.5% or $820,529 Net Income (Loss) the first six months of 2025 improved 29% to a loss of $273,479 Non-GAAP EBITDA(1) the first six months of 2025 improved 151% or $142,091 IDAHO FALLS, IDAHO, August 13,...
by Clay Adams | May 20, 2025 | Press Release
Sale of product for first quarter increased 12% to $3.2 million. Nuclear Medicine Standards sale of product in the first quarter increased 73% to $1.3 million. Net Income (Loss) improved 27% to a loss of $112,694, with Non-GAAP EBITDA(1)of $7,075, and Non-GAAP...
Recent Comments